195 related articles for article (PubMed ID: 20161984)
21. Long-term studies on the stability and oral bioavailability of cyclosporine A nanoparticle colloid.
Wang XQ; Huang J; Dai JD; Zhang T; Lü WL; Zhang H; Zhang X; Wang JC; Zhang Q
Int J Pharm; 2006 Sep; 322(1-2):146-53. PubMed ID: 16787721
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of Orally Administered Poly(Ethylene Oxide)-block-Poly(ε-Caprolactone) Micelles of Cyclosporine A in Rats: Comparison with Neoral®.
Binkhathlan Z; Ali R; Qamar W; Lavasanifar A
J Pharm Pharm Sci; 2018; 21(1s):192s-199s. PubMed ID: 30139426
[TBL] [Abstract][Full Text] [Related]
23. Biodegradable nanoparticles as a delivery system for cyclosporine: preparation and characterization.
Molpeceres J; Aberturas MR; Guzman M
J Microencapsul; 2000; 17(5):599-614. PubMed ID: 11038119
[TBL] [Abstract][Full Text] [Related]
24. Controlled release of cyclosporine A self-nanoemulsifying systems from osmotic pump tablets: near zero-order release and pharmacokinetics in dogs.
Zhang X; Yi Y; Qi J; Lu Y; Tian Z; Xie Y; Yuan H; Wu W
Int J Pharm; 2013 Aug; 452(1-2):233-40. PubMed ID: 23688622
[TBL] [Abstract][Full Text] [Related]
25. Sylysia 350/Eudragit S100 solid nanomatrix as a promising system for oral delivery of cyclosporine A.
Dai W; Guo Y; Zhang H; Wang X; Zhang Q
Int J Pharm; 2015 Jan; 478(2):718-25. PubMed ID: 25448562
[TBL] [Abstract][Full Text] [Related]
26. Duodenum-triggered delivery of pravastatin sodium: II. Design, appraisal and pharmacokinetic assessments of enteric surface-decorated nanocubosomal dispersions.
Tayel SA; El-Nabarawi MA; Tadros MI; Abd-Elsalam WH
Drug Deliv; 2016 Nov; 23(9):3266-3278. PubMed ID: 27094305
[TBL] [Abstract][Full Text] [Related]
27. Fabrication of novel GMO/Eudragit E100 nanostructures for enhancing oral bioavailability of carvedilol.
Patil SS; Roy K; Choudhary B; Mahadik KR
Drug Dev Ind Pharm; 2016 Aug; 42(8):1300-7. PubMed ID: 26651381
[TBL] [Abstract][Full Text] [Related]
28. A nanostructured liquid crystalline formulation of 20(S)-protopanaxadiol with improved oral absorption.
Jin X; Zhang ZH; Li SL; Sun E; Tan XB; Song J; Jia XB
Fitoterapia; 2013 Jan; 84():64-71. PubMed ID: 23006538
[TBL] [Abstract][Full Text] [Related]
29. [Preparation of cyclosporine A loaded mPEG-PLGA copolymer micelles and study its pharmacokinetics in rats].
Yao DG; Sun KX; Mu HJ; Zhou FM; Chen HH; Liu LJ; Liang N
Yao Xue Xue Bao; 2009 Dec; 44(12):1410-5. PubMed ID: 21351479
[TBL] [Abstract][Full Text] [Related]
30. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals.
Müller RH; Runge S; Ravelli V; Mehnert W; Thünemann AF; Souto EB
Int J Pharm; 2006 Jul; 317(1):82-9. PubMed ID: 16580159
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic and Tissue Distribution of Orally Administered Cyclosporine A-Loaded poly(ethylene oxide)-block-Poly(ε-caprolactone) Micelles versus Sandimmune
Binkhathlan Z; Ali R; Qamar W; Al-Lawati H; Lavasanifar A
Pharm Res; 2021 Jan; 38(1):51-65. PubMed ID: 33559046
[TBL] [Abstract][Full Text] [Related]
32. Spray dried glyceryl monooleate-magnesium trisilicate dry powder as cubic phase precursor.
Shah MH; Biradar SV; Paradkar AR
Int J Pharm; 2006 Oct; 323(1-2):18-26. PubMed ID: 16846704
[TBL] [Abstract][Full Text] [Related]
33. Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation.
Nguyen TH; Hanley T; Porter CJ; Larson I; Boyd BJ
J Pharm Pharmacol; 2010 Jul; 62(7):856-65. PubMed ID: 20636873
[TBL] [Abstract][Full Text] [Related]
34. [Influence of suspending agents on relative bioavailability of cyclosporine A-loaded HPMCP nanoparticles for oral administration to rats].
Wang XQ; Chen Z; Dai JD; Zhang T; Xia GM; Zhang Q
Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Jun; 36(3):305-8. PubMed ID: 15205706
[TBL] [Abstract][Full Text] [Related]
35. Absorption mechanism of cyclosporine A loaded pH-sensitive nanoparticles in rats.
Wang XQ; Dai JD; Zhang H; Zhang X; Wang JC; Zhang Q
J Nanosci Nanotechnol; 2008 May; 8(5):2422-31. PubMed ID: 18572658
[TBL] [Abstract][Full Text] [Related]
36. Improved oral bioavailability of repaglinide, a typical BCS Class II drug, with a chitosan-coated nanoemulsion.
Karami Z; Saghatchi Zanjani MR; Nasihatsheno N; Hamidi M
J Biomed Mater Res B Appl Biomater; 2020 Apr; 108(3):717-728. PubMed ID: 31187938
[TBL] [Abstract][Full Text] [Related]
37. Transition from Amorphous Cyclosporin A Nanoparticles to Size-Reduced Stable Nanocrystals in a Poloxamer 407 Solution.
Chen Z; Higashi K; Ueda K; Moribe K
Mol Pharm; 2022 Jan; 19(1):188-199. PubMed ID: 34843257
[TBL] [Abstract][Full Text] [Related]
38. Lipid nanoparticles enhance the absorption of cyclosporine A through the gastrointestinal barrier: In vitro and in vivo studies.
Guada M; Lasa-Saracíbar B; Lana H; Dios-Viéitez Mdel C; Blanco-Prieto MJ
Int J Pharm; 2016 Mar; 500(1-2):154-61. PubMed ID: 26794875
[TBL] [Abstract][Full Text] [Related]
39. Polymeric nanocapsules with SEDDS oil-core for the controlled and enhanced oral absorption of cyclosporine.
Park MJ; Balakrishnan P; Yang SG
Int J Pharm; 2013 Jan; 441(1-2):757-64. PubMed ID: 23089581
[TBL] [Abstract][Full Text] [Related]
40. Solid self-nanoemulsifying cyclosporine A pellets prepared by fluid-bed coating: stability and bioavailability study.
Lei Y; Qi J; Nie S; Hu F; Pan W; Lu Y; Wu W
J Biomed Nanotechnol; 2012 Jun; 8(3):515-21. PubMed ID: 22764422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
